SCYNEXIS, Inc. (SCYX) News
Track canonical SquawkNews coverage tagged to SCYX, SCYNEXIS, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 21 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Scynexis Secures Up to $214 Million BARDA Cost-Share Award to Advance SCY-247
Scynexis entered into a cost-share BARDA Contract to fund development of SCY-247, a second-generation fungerp antifungal. The award provides up to $214 million in non-dilutive support, including an $18.5 million base per
NEWS | Sep 28, 2026, 08:06 PM UTC
L
SCYNEXIS, Inc. (SCYX) Wins BARDA Contract Worth Up To $214M
SCYNEXIS was awarded a BARDA contract providing up to $214M if all options are exercised to develop SCY-247 through potential NDA submissions. The base period provides ~$18.5M to advance oral and IV SCY-247 into a Phase
NEWS | Sep 28, 2026, 11:32 AM UTC
L
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. NASDAQ:SCYX (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases,
NEWS | Sep 28, 2026, 11:32 AM UTC
M
SCYNEXIS awarded BARDA contract for SCY-247 development
SCYNEXIS said BARDA awarded it a contract providing up to $214 million in non-dilutive funding for development of SCY-247.
EQUITY | Sep 28, 2026, 11:30 AM UTC
L
SCYX - SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
SCYX - SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
NEWS | Sep 22, 2026, 12:00 PM UTC
L
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
Experienced biopharmaceutical and nephrology leader joins SCYNEXIS to advance its rare disease development programsJERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. NASDAQ:SCYX (the Company or SCYNEXIS
NEWS | Sep 15, 2026, 12:03 PM UTC
L
SCYX - SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
SCYX - SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
NEWS | Sep 15, 2026, 12:02 PM UTC
L
SCYNEXIS appoints Sanjay Subramanian as CFO
EQUITY | Sep 10, 2026, 12:41 PM UTC
M
SCYNEXIS names Sanjay Subramanian CFO as Ivor Macleod retires
SCYNEXIS appointed Sanjay Subramanian as chief financial officer effective September 9, 2026. Ivor Macleod retired from the CFO role effective the same date and will remain through October 9, 2026 to support the transiti
EQUITY | Sep 10, 2026, 12:14 PM UTC
L
Scynexis Macleod to remain through Oct 9
EQUITY | Sep 10, 2026, 12:04 PM UTC
L
Scynexis CFO Ivor Macleod retires effective Sept. 9
EQUITY | Sep 10, 2026, 12:04 PM UTC
L
Scynexis Subramanian appointment effective Sept. 9
EQUITY | Sep 10, 2026, 12:03 PM UTC
L
SCYNEXIS appoints Sanjay Subramanian as chief financial officer
EQUITY | Sep 10, 2026, 12:03 PM UTC
L
SCYNEXIS appoints Sanjay Subramanian as CFO
EQUITY | Sep 10, 2026, 12:01 PM UTC
L
SCYNEXIS to participate in upcoming investor conferences
SCYNEXIS, Inc. says it will participate in upcoming investor conferences, according to a company announcement.
EQUITY | Sep 01, 2026, 12:37 PM UTC
L
SCYX - SCYNEXIS to Participate in Upcoming Investor Conferences
SCYX - SCYNEXIS to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 12:31 PM UTC
H
SCYX Surges 27%
SCYX rises 27%
EQUITY | Jul 31, 2026, 07:00 PM UTC
H
Watching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pedi
Watching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pediatric Use Information And Revised Patient Safety Guidance
REGULATION | Jul 31, 2026, 04:04 PM UTC
H
SCYX resumes trading, now +8%
SCYX trading resumes with 8% gain
EQUITY | Jul 31, 2026, 04:03 PM UTC
H
SCYX Halted on Downside Volatility
SCYX trading halted due to volatility
EQUITY | Jul 31, 2026, 03:58 PM UTC
L
SCYNEXIS Starts Phase 1 Trial Of SCY-770 Activator Of Two Dosing Regimens
SCYNEXIS, Inc. (NASDAQ: SCYX ), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct AMP
EQUITY | Jun 30, 2026, 12:02 PM UTC